BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

Bertrand Bodson, chief digital officer at Novartis AG (NYSE:NVS; SIX:NOVN), will step down from the pharma’s executive committee on Feb. 1. Bodson took on the newly created role at Novartis in January 2018 to integrate new...
BioCentury | Dec 12, 2020
Regulation

RNA therapies get another 2020 win with inclisiran approval

The migration of new modalities into prevalent indications took another step forward on Friday with the European Commission’s approval of Novartis’ siRNA therapy Leqvio inclisiran to treat hypercholesterolemia...
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Sep 2, 2020
Management Tracks

Career officials Rebello, Felberbaum to lead FDA’s communications

Former FDA commissioners Scott Gottlieb and Robert Califf tweeted their praise Tuesday of the appointment of two long-time FDA officials to head the agency’s communications.  Heidi Rebello will become FDA’s acting associate commissioner for external...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

Patient death prompts Cellectis trial halt FDA placed a clinical hold on an allogeneic CAR T therapy trial to treat multiple myeloma from Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) after a patient who received the second-level dose...
BioCentury | May 9, 2020
Finance

Ayala becomes latest to join the year’s bumper crop of biopharma IPOs

Ayala’s public debut late Thursday adds to the more than $4 billion raised from global biopharma IPOs so far this year. This year is outpacing 2019 for total funds raised in IPOs even as investors...
BioCentury | Apr 20, 2020
Finance

French VC Sofinnova expanding start-up ecosystem in Italy with new local fund’s first investments

With the first three investments from a new fund launched in partnership with Italian charity Fondazione Telethon to invest in therapies for rare genetic diseases, Sofinnova Partners is aiming to build and expand the country’s...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
Items per page:
1 - 10 of 292